Literature DB >> 7812981

Lung cancer in the young.

M P Rocha1, A E Fraire, K K Guntupalli, S D Greenberg.   

Abstract

Lung cancer is uncommon in individuals age 40 or less. We reviewed the Cancer Registry files of the Ben Taub General Hospital (Houston, TX) from 1971 to 1989 and identified 1678 patients with a documented diagnosis of lung cancer. Among these 1678 patients, 50 (2.98%) were age 40 or less. Thirty-five (70%) of the 50 patients were men and 15 (30%) were women. Their median age was 37 (range of 24 to 40). A smoking history was available in 37 patients. Thirty-five (94.5%) of the 37 patients who were smokers had a > 20-pack per year history of smoking. Four patients were intravenous drug abusers, and one of these four tested positive for the immunodeficiency virus. Twenty-seven (54%) had adenocarcinoma, eight (16%) had squamous cell carcinoma, and six (12%) had other nondescript, nonsmall-cell carcinoma types. In contrast, the proportion of adenocarcinoma for the (all-age) group of 1678 patients with lung cancer was 28.2%. This difference in the proportion of adenocarcinoma between the two age groups was statistically significant (Pearson's Chi 2, 13.7039, p < 0.0005). Thirty-one (77.5%) of the 50 patients had unresectable disease at diagnosis (12 had stage IIIb and 19 had stage IV). The median survival from diagnosis was 26 weeks. These findings suggest that (1) smoking is an important risk factor for this subset of young patients, (2) the proportion of adenocarcinoma is higher in the young compared with the entire group of lung cancer patients, which included patients of all ages, and (3) young patients tend to present with advanced disease at diagnosis, resulting in an extremely poor survival.

Entities:  

Mesh:

Year:  1994        PMID: 7812981

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  7 in total

1.  Lung cancer in individuals less than 50 years of age.

Authors:  Guntulu Ak; Muzaffer Metintas; Selma Metintas; Huseyin Yildirim; Sinan Erginel; Fusun Alatas
Journal:  Lung       Date:  2007-08-20       Impact factor: 2.584

2.  Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States.

Authors:  Anish Thomas; Yuanbin Chen; Tinghui Yu; Marko Jakopovic; Giuseppe Giaccone
Journal:  Front Oncol       Date:  2015-05-26       Impact factor: 6.244

3.  A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients.

Authors:  Preenumol Thomas; Bini Vincent; Christeena George; Julie Mariam Joshua; K Pavithran; Meenu Vijayan
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

4.  Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals.

Authors:  Yuqing Lou; Qin Shi; Yanwei Zhang; Ying Qi; Wei Zhang; Huimin Wang; Jun Lu; Baohui Han; Hua Zhong
Journal:  Front Cell Dev Biol       Date:  2022-03-10

5.  Genomic landscape of lung cancer in the young.

Authors:  Rossana Ruiz; Marco Galvez-Nino; Katia Roque; Jaime Montes; Maria Nuñez; Luis Raez; Sergio Sánchez-Gambetta; Sandra Jaúregui; Sandra Viale; Edward S Smith; Joseph A Pinto; Luis Mas
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

6.  Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years.

Authors:  Albert Rosenberger; Thomas Illig; Katrin Korb; Norman Klopp; Vera Zietemann; Gabi Wölke; Eckart Meese; Gerhard Sybrecht; Florian Kronenberg; Matthias Cebulla; Maria Degen; Peter Drings; Andreas Gröschel; Nikolaus Konietzko; Karsten Grosse Kreymborg; Karl Häussinger; Gerd Höffken; Bettina Jilge; You-Dschun Ko; Harald Morr; Christine Schmidt; E-Wilhelm Schmidt; Dagmar Täuscher; Heike Bickeböller; H-Erich Wichmann
Journal:  BMC Cancer       Date:  2008-02-25       Impact factor: 4.430

7.  Lung cancer in young patients: tumour characteristics and treatment in an Irish population.

Authors:  Sarah Cullivan; Sarah Ni Mhaolcatha; Michael T Henry; Nazri Kaderi Muhammad; William Mullally; Richard M Bambury; Louise Burke; Marcus P Kennedy
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.